VCID Biomarker's Coordinating Center

项目总结/摘要 脑小血管疾病导致的认知障碍和痴呆（VCID）的血管贡献 (SVD)现在被认为是一个重大的公共卫生威胁。为了响应NINDS关于多站点的呼吁， 致力于鉴定和验证SVD相关VCID生物标志物的联盟，我们建议成立 马萨诸塞州总医院（MGH）VCID生物标志物协调中心。建议的目标 协调中心将提供杰出的科学领导和最先进的行政和 VCID生物标志物联盟的数据管理基础设施。拟定MGH的具体规格 协调中心包括1）主要研究者作为科学先驱的高水平技能， SVD生物标志物和复杂的多中心项目和组织的有效领导者，2）杰出的 以及经验丰富的管理和数据核心负责人、合作研究者和研究工作人员团队，能够 处理复杂协调中心的所有方面，3）多模式数据处理的创新方法 最大限度地减少MRI数据中的扫描仪间变化，以及4）详细的组织计划， 代表委员会的决策，为数据收集制定联合标准， 共享、全联盟范围内的沟通以及与相关外部努力的外联。如果被选中， MGH协调中心将处于理想的位置，以领导联合体实现其移动SVD的目标 生物标志物应用于VCID临床试验的前沿。

PROJECT SUMMARY/ABSTRACT The vascular contribution to cognitive impairment and dementia (VCID) driven by cerebral small vessel disease (SVD) is now recognized as a major public health threat. In response to the call from NINDS for a multisite consortium dedicated to identifying and validating biomarkers for SVD-related VCID, we propose to form the Massachusetts General Hospital (MGH) VCID Biomarkers Coordinating Center. The aims of the proposed coordinating center will be to provide outstanding scientific leadership and state-of-the-art administrative and data management infrastructure to the VCID biomarkers consortium. Specific strengths of the proposed MGH coordinating center include 1) the Principal Investigator's demonstrated high-level skill as a scientific pioneer in SVD biomarkers and an effective leader of complex multicenter projects and organizations, 2) an outstanding and experienced team of Administrative and Data Core directors, co-Investigators, and study staff capable of handling all aspects of a complex coordinating center, 3) innovative approaches to multimodal data handling and minimizing inter-scanner variations in MRI data, and 4) detailed organizational plans for efficient high-level decision-making by representative committees, creation of consortium standards for data collection and sharing, consortium-wide communication, and outreach to related external efforts. If selected, the proposed MGH coordinating center will be ideally positioned to lead the consortium to its goals of moving SVD biomarkers to the forefront of VCID clinical trials.